Centessa Pharma reports Q2 results, highlights orexin agonist franchise progress.

• Centessa reports financial results for Q2 2025 • Orexin receptor 2 agonist franchise advances with key data readouts expected • ORX750 Phase 2a CRYSTAL-1 study for narcolepsy, hypersomnia on track • ORX142 Phase 1 clinical trial underway for neurological disorders • ORX489 in IND-enabling studies for neuropsychiatric disorders • First-in-class potential in narcolepsy type 2 and idiopathic hypersomnia

Centessa Pharmaceuticals plc (Nasdaq: CNTA) has reported its financial results for the second quarter ended June 30, 2025, and provided updates on its orexin receptor 2 (OX2R) agonist pipeline. The company reported a net loss of $50.3 million for the quarter, compared to $43.8 million for the same period last year. Cash, cash equivalents, and investments totaled $404.1 million as of June 30, 2025, with the company expecting these funds to cover operations through mid-2027. Research & Development (R&D) expenses were $42.7 million, up from $32.8 million in the same period last year, while General & Administrative (G&A) expenses were $11.9 million, up from $11.2 million [1].

The company's orexin receptor 2 agonist pipeline continues to advance with key data readouts expected this year. The ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) is on track, with data expected in all three indications. ORX750 has first-in-class potential in NT2 and IH. The ORX142 Phase 1 clinical trial for the treatment of select neurological and neurodegenerative disorders is also underway, with data in acutely sleep-deprived healthy volunteers expected this year. Additionally, ORX489 is in IND-enabling studies for the treatment of neuropsychiatric disorders [1].

The company's CEO, Saurabh Saha MD PhD, stated, "As clinical validation of the orexin agonist class continues to grow, we believe Centessa is well positioned with a novel potential best-in-class OX2R agonist pipeline aimed at redefining the standard of care... Our top priority remains the successful execution of the Phase 2a study, and we look forward to sharing data for ORX750 in all three indications this year." [1]

References:
[1] https://www.investegate.co.uk/announcement/gnw/centessa-pharmaceuticals-adr--0acx/centessa-pharmaceuticals-reports-financial-re-/9047104